chargement...
An advisory committee recommended on Thursday, December 17, granting an emergency authorization in the United States to Moderna vaccine.
According to Agence France-Presse (AFP), the US drug agency should now give the green light to this vaccine, as it did for Pfizer's on December 11 following a similar opinion.
This opinion was backed with 20 votes and only one abstention. Like Pfizer's, the vaccine will not be recommended for people who may develop allergic reactions.
These two vaccines are based on a new technology, messenger RNA, and allergic reactions have been observed in two people who received the vaccine from Pfizer in the United Kingdom, and two others in the United States, recalls AFP.
Moderna filed its emergency authorization request two and a half weeks ago. The young Massachusetts-based biotechnology company began work on its vaccine in January 2020, in collaboration with the US National Institutes of Health. It has received public funding of $ 2.5 billion for this.
AFP also recalls that the US government has pre-purchased 200 million doses of Moderna's vaccine and 100 million from Pfizer.
